Calvin Goforth, PhD

Calvin Goforth, PhD
Calvin Goforth, PhD, VIC Founder and Chief Executive Officer, has extensive experience in start-up company development in founder, investor, board member, and executive roles. His experience encompasses intellectual property assessment, building strong development teams, raising private investment and government funding, and bringing products to market. He received a BS in Aerospace Engineering with Highest Honors from the University of Texas at Austin.
Find me on:

Recent Posts

A Letter from our CEO

As CEO of VIC Tech, I am fortunate to have the opportunity to review exciting new life science technologies on an ongoing basis and regularly speak with life science thought leaders, inventors, investors, and large...

Our Life Science and Healthcare Future

Dramatic life science advancements are emerging that are likely to transform healthcare over the next 20 years. For example, continued rapid progress of cell and gene therapies will offer a complete cure for a wide...

Individual Investor Access to VC Stage Investments

In my last article, I discussed why individual investors should include privately held, innovation-driven companies in a diversified and balanced investment strategy [Seven Reasons Venture Capital-Stage Companies Should...

Seven Reasons Venture Capital-Stage Companies Should Become Part of Your Investment Portfolio

We live in eventful times. The world is changing at a dizzying pace…inflation, war and geopolitical instability, climate change, the pandemic, and supply chain issues are just a few of the important change factors. And...

SAFE vs. Convertible Notes: Which is a Better Choice for Early-Stage Investments?

Experienced early-stage investors are familiar with convertible note investments, which have evolved slightly but have been around in largely the same form for more than two decades. Convertible note investments start...

Letter from the CEO

It has been a year and ten months since the World Health Organization declared COVID-19 a pandemic. Despite the continuing pandemic, VIC’s business has largely returned to normal albeit with increased remote work, more...

University Technology Licensing Part 2: Assessing the Opportunities and Negotiating Licenses

Part 2: Technology Transfer and License Terms As was described in Part I of this article [1], VIC has a systematic and thorough technology assessment process. We also have extensive experience negotiating licenses for...

University Technology Licensing: Assessing the Opportunities and Negotiating Licenses

Part 1: Opportunity Sourcing and Assessment The U.S. invests more than $120 billion in federally sponsored research funding at universities and national labs. Technology Transfer Offices (TTOs) are unique entities...

Building Life Science Startups Beyond Traditional Venture Capital Hubs

Innovation is Geographically Distributed; Venture Capital Activity is Not The powerful combination of venture capital and innovation is critical to maintaining the global competitiveness of the U.S. While innovation is...

Zero Federal Capital Gains Taxes on High-Return Investments

With a new administration comes new perspectives and likely changes in tax policy. President Biden has proposed doubling the rate that wealthy Americans pay on investment capital gains up to 43.4%, a topic that has been...


VIC Tech Continues to Grow Its Medical Advisory Board
Zero Federal Capital Gains Taxes on High-Return Investments
White Paper
Portfolio Diversification in Times of Market Volatility
Inside CTTC at Vanderbilt University with Assistant Director, Physical Sciences Ashok Choudhury
Seven Reasons Venture Capital-Stage Companies Should Become Part of Your Investment Portfolio
White Paper
Investing in Medical Devices & Diagnostics – Industry Trends and Investor Activity
Cellia Science Formed to Develop and Commercialization Point-of-Care Hematology Analyzers
VIC Fellows Spotlight: Alexandra Antonioli, MD, PhD
From The Corner Office
SFC Fluidics Nears FDA Submission